Thrivent Financial for Lutherans’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Thrivent Financial for Lutherans’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-6,819	Closed	-$620K	–	2558
2023 Q1	$620K	Sell	6,819 -66,555	-91%	-$3.91M	﹤0.01%	2036
2022 Q4	$2.79M	Buy	73,374 +36,156	+97%	+$1.24M	0.01%	1048
2022 Q3	$935K	Buy	+37,218	New	+$1.03M	﹤0.01%	1725
2021 Q4	–	Sell	-39,135	Closed	-$3.94M	–	2517
2021 Q3	$3.94M	Sell	39,135 -75	-0.2%	-$8.79K	0.01%	995
2021 Q2	$5.55M	Sell	39,210 -12,211	-24%	-$1.38M	0.01%	870
2021 Q1	$5.13M	Sell	51,421 -2,192	-4%	-$256K	0.01%	907
2020 Q4	$6.63M	Buy	53,613 +39,824	+289%	+$5.23M	0.02%	777
2020 Q3	$1.34M	Sell	13,789 -818	-6%	-$102K	﹤0.01%	1392
2020 Q2	$2.28M	Hold	14,607	–	–	0.01%	992
2020 Q1	$2.11M	Buy	+14,607	New	+$2.82M	0.01%	929

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Thrivent Financial for Lutherans's RETA Position: Q2 2023 in Review

Thrivent Financial for Lutherans sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2023, closing a stake of 6,819 shares — an estimated $620K sold.

Thrivent Financial for Lutherans first reported a position in RETA in Q1 2020 and held it in 10 quarters. The position peaked at $6.63M in Q4 2020. 214 funds tracked by Wall St. Rank hold RETA as of Q2 2023.

Thrivent Financial for Lutherans reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Thrivent Financial for Lutherans sold 6,819 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2023, an estimated $620K.
Thrivent Financial for Lutherans first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2020 and held it in 10 quarters.
Thrivent Financial for Lutherans's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $6.63M in Q4 2020.
214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2023.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2023, filed 14 Aug 2023.